|
Real-time
Boerse Muenchen
06:44:23 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 0.3915 EUR | +8.15% |
|
0.00% | +21.68% |
| 08-27 | The FDA will issue its decision on Nicox's NCX 470 by the end of next April |  |
| 08-27 | US FDA to Complete Nicox's Glaucoma Drug Review by April 2027 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 39.28M | - | - | - | ||
| 374B | |||||
| 70.56B | |||||
| 12.45B | |||||
| 7.89B | |||||
| 4.98B |
- Stock Market
- Stocks
- ALCOX Stock
- NXOA Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
